AVGO vs. LLY: Broadcom vs. Eli Lilly Stock Comparison
This page compares Broadcom (AVGO) with Eli Lilly (LLY) using performance and risk, profitability, financial strength, growth, dividends, and valuation metrics.
Performance
Cumulative Growth
Trailing Returns
Performance at a Glance
| Metric | AVGO | LLY |
|---|---|---|
| 1-Year Return | 50.41% | 40.51% |
Risk
Drawdown
Broadcom (AVGO) has an aggressive beta of 1.46, indicating higher sensitivity to broad-market moves, while Eli Lilly (LLY) is defensive at 0.51 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.
Risk at a Glance
| Metric | AVGO | LLY |
|---|---|---|
| 1-Year Volatility | 45.65% | 38.09% |
| Beta | 1.46 | 0.51 |
| 3-Month Avg. Volume | 25.57M | 3.19M |
Company Profile
Broadcom (AVGO) is classified in the Information Technology sector (Semiconductors & Semiconductor Equipment), whereas Eli Lilly (LLY) belongs to Health Care (Pharmaceuticals, Biotechnology & Life Sciences) — their GICS classifications point to very different parts of the market.
| Profile Item | AVGO | LLY |
|---|---|---|
| Name | Broadcom Inc. | Eli Lilly and Company |
| Country/Region | United States | United States |
| GICS Sector | Information Technology | Health Care |
| GICS Industry Group | Semiconductors & Semiconductor Equipment | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Semiconductors & Semiconductor Equipment | Pharmaceuticals |
| GICS Sub-Industry | Semiconductors | Pharmaceuticals |
| Market Capitalization | 1,817.73 billion USD | 1,010.34 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | August 6, 2009 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Valuation
Price-to-Earnings Ratio (TTM)
Both Broadcom (AVGO) at 63.68 and Eli Lilly (LLY) at 40.32 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
AVGO
Semiconductors & Semiconductor Equipment industry group
63.68
- Max
- 261.27
- Q3
- 146.72
- Median
- 71.81
- AVGO
- 63.68
- Q1
- 47.83
- Min
- 6.57
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.32
- Max
- 77.14
- Q3
- 43.78
- LLY
- 40.32
- Median
- 24.68
- Q1
- 15.27
- Min
- 1.70
Price-to-Sales Ratio (TTM)
Eli Lilly (LLY) at 13.98 is priced about in line with its industry on P/S ratio, while Broadcom (AVGO) at 24.09 sits in the pricier quartile — AVGO costs more per dollar of sales.
AVGO
Semiconductors & Semiconductor Equipment industry group
24.09
- Max
- 37.84
- AVGO
- 24.09
- Q3
- 22.05
- Median
- 10.55
- Q1
- 4.79
- Min
- 0.02
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.98
- Max
- 55.38
- Q3
- 24.42
- LLY
- 13.98
- Median
- 6.98
- Q1
- 3.30
- Min
- 0.01
Price-to-Book Ratio (MRQ)
Both look rich against book: Broadcom (AVGO) at 20.73 sits in the upper P/B ratio quartile, and Eli Lilly (LLY) at 32.45 prices even higher, above its industry range.
AVGO
Semiconductors & Semiconductor Equipment industry group
20.73
- Max
- 27.08
- AVGO
- 20.73
- Q3
- 14.21
- Median
- 7.77
- Q1
- 3.94
- Min
- 0.24
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.45
- LLY
- 32.45
- Max
- 13.23
- Q3
- 6.38
- Median
- 3.46
- Q1
- 1.64
- Min
- -5.17
Valuation at a Glance
| Metric | AVGO | LLY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 63.68 | 40.32 |
| Price-to-Sales Ratio (TTM) | 24.09 | 13.98 |
| Price-to-Book Ratio (MRQ) | 20.73 | 32.45 |
| Free Cash Flow Yield | 1.50% | 0.91% |
Profitability
Return on Equity (TTM)
Both companies show strong equity returns, but Eli Lilly (LLY) at 107.46% is the standout with ROE above its industry range; Broadcom (AVGO) at 37.28% also sits in the top quartile.
AVGO
Semiconductors & Semiconductor Equipment industry group
37.28%
- Max
- 39.82%
- AVGO
- 37.28%
- Q3
- 17.02%
- Median
- 6.39%
- Q1
- -5.42%
- Min
- -35.15%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
107.46%
- LLY
- 107.46%
- Max
- 101.32%
- Q3
- 2.92%
- Median
- -31.26%
- Q1
- -62.68%
- Min
- -158.89%
Net Profit Margin (TTM)
Eli Lilly (LLY) at 34.99% keeps the most of each sales dollar — above its industry’s net margin range — and Broadcom (AVGO) at 38.85% also retains a top-quartile share.
AVGO
Semiconductors & Semiconductor Equipment industry group
38.85%
- Max
- 57.72%
- AVGO
- 38.85%
- Q3
- 20.92%
- Median
- 7.04%
- Q1
- -4.69%
- Min
- -32.92%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.99%
- LLY
- 34.99%
- Max
- 12.76%
- Q3
- 4.00%
- Median
- 0.00%
- Q1
- -2.26%
- Min
- -11.53%
Operating Profit Margin (TTM)
Both Broadcom (AVGO) at 48.99% and Eli Lilly (LLY) at 49.39% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
AVGO
Semiconductors & Semiconductor Equipment industry group
48.99%
- Max
- 65.60%
- AVGO
- 48.99%
- Q3
- 21.10%
- Median
- 9.27%
- Q1
- -8.85%
- Min
- -46.64%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
49.39%
- Max
- 100.30%
- LLY
- 49.39%
- Q3
- 4.40%
- Median
- 0.00%
- Q1
- -131.52%
- Min
- -333.43%
Profitability at a Glance
| Metric | AVGO | LLY |
|---|---|---|
| Return on Equity (TTM) | 37.28% | 107.46% |
| Return on Assets (TTM) | 12.12% | 20.74% |
| Net Profit Margin (TTM) | 38.85% | 34.99% |
| Operating Profit Margin (TTM) | 48.99% | 49.39% |
| Gross Profit Margin (TTM) | 76.28% | 82.83% |
Growth
Revenue Growth
Revenue Growth at a Glance
| Metric | AVGO | LLY |
|---|---|---|
| 1-Year Revenue Growth | 23.87% | 44.70% |
| 3-Year Revenue CAGR | 24.38% | 31.69% |
EPS Growth
EPS Growth at a Glance
| Metric | AVGO | LLY |
|---|---|---|
| 1-Year EPS Growth | 287.80% | 95.99% |
| 3-Year EPS CAGR | 21.60% | 51.71% |
Financial Strength
Current Ratio (MRQ)
Both Broadcom (AVGO) at 2.24 and Eli Lilly (LLY) at 1.50 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
AVGO
Semiconductors & Semiconductor Equipment industry group
2.24
- Max
- 11.30
- Q3
- 6.09
- Median
- 3.28
- Q1
- 2.37
- AVGO
- 2.24
- Min
- 0.51
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.50
- Max
- 24.81
- Q3
- 11.75
- Median
- 5.57
- Q1
- 2.69
- LLY
- 1.50
- Min
- 0.23
Debt-to-Equity Ratio (MRQ)
Both Broadcom (AVGO) at 0.74 and Eli Lilly (LLY) at 1.39 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.
AVGO
Semiconductors & Semiconductor Equipment industry group
0.74
- Max
- 1.44
- AVGO
- 0.74
- Q3
- 0.63
- Median
- 0.20
- Q1
- 0.04
- Min
- 0.00
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 1.60
- LLY
- 1.39
- Q3
- 0.68
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength at a Glance
| Metric | AVGO | LLY |
|---|---|---|
| Current Ratio (MRQ) | 2.24 | 1.50 |
| Debt-to-Equity Ratio (MRQ) | 0.74 | 1.39 |
| Net Debt / EBITDA | 1.08 | 1.05 |
Dividends
Dividend Yield (TTM)
Broadcom (AVGO) at 0.68% earns its spot in the top quartile of its industry’s yields; Eli Lilly (LLY) at 0.61% is past the top of its own peer range — territory where a dividend-safety check matters more than the headline number.
AVGO
Semiconductors & Semiconductor Equipment industry group
0.68%
- Max
- 0.93%
- AVGO
- 0.68%
- Q3
- 0.39%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.61%
- LLY
- 0.61%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Both pay out more than their industries’ typical bands, and LLY more so: Broadcom (AVGO) at 41.26% sits above the band, while Eli Lilly (LLY) at 22.13% exceeds every peer in its group.
AVGO
Semiconductors & Semiconductor Equipment industry group
41.26%
- AVGO
- 41.26%
- Max
- 41.26%
- Q3
- 19.10%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.13%
- LLY
- 22.13%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividends at a Glance
| Metric | AVGO | LLY |
|---|---|---|
| Dividend Yield (TTM) | 0.68% | 0.61% |
| Dividend Payout Ratio (TTM) | 41.26% | 22.13% |